The DOI matches its Crossref record; 148 of the 158 references it cites were found in a registry or an index; 58 of the 131 sources its claims cite were checked for support.
The p53 Pathway in Glioblastoma
Open accessAbstract
The tumor suppressor and transcription factor p53 plays critical roles in tumor prevention by orchestrating a wide variety of cellular responses, including damaged cell apoptosis, maintenance of genomic stability, inhibition of angiogenesis, and regulation of cell metabolism and tumor microenvironment. TP53 is one of the most commonly deregulated genes in cancer. The p53-ARF-MDM2 pathway is deregulated in 84% of glioblastoma (GBM) patients and 94% of GBM cell lines. Deregulated p53 pathway components have been implicated in GBM cell invasion, migration, proliferation, evasion of apoptosis, and cancer cell stemness. These pathway components are also regulated by various microRNAs and long non-coding RNAs. TP53 mutations in GBM are mostly point mutations that lead to a high expression of a gain of function (GOF) oncogenic variants of the p53 protein. These relatively understudied GOF p53 mutants promote GBM malignancy, possibly by acting as transcription factors on a set of genes other than those regulated by wild type p53. Their expression correlates with worse prognosis, highlighting their potential importance as markers and targets for GBM therapy. Understanding mutant p53 functions led to the development of novel approaches to restore p53 activity or promote mutant p53 degradation for future GBM therapies.
Overview
CoChat Summary
TL;DR
This review summarizes the p53 pathway in glioblastoma, emphasizing frequent deregulation of p53-ARF-MDM2 components and the understudied oncogenic gain-of-function (GOF) mutant p53. It discusses mechanisms of GOF mut-p53 and therapeutic strategies to restore wild-type p53 or degrade mutant p53.
Key findings
- The p53-ARF-MDM2 pathway is deregulated in 237/281 (84%) of GBM in TCGA and up to 94.1% of GBM cell lines; individual components are deregulated at TP53 22%, ARF 61%, MDM2 10%, and MDM4 10%, while CDKN2A/ARF homozygous deletion occurs in ~60% of GBM.
- TP53 mutations occur in ~28% of tumors, with subtype prevalence of 54% proneural, 32% mesenchymal, 21% neural, and 0% classical; most are missense DNA-binding domain mutations, and >25% occur in six hotspots (R273, R248, R175, G245, R282, R249), producing highly expressed GOF mut-p53.
- GOF mut-p53 promotes proliferation, migration, invasion, chemotherapy resistance, altered metabolism, and stemness; it can exert dominant-negative effects on wt-p53 and interact with p63/p73 and other transcription factors. The review notes TP53 mutational status has not been correlated with survival in GBM despite high mutation frequency, while GOF mut-p53 remains understudied.
- Therapeutic approaches include MDM2/p53 inhibitors (e.g., nutlin3a, RG7112, AMG232), mutant p53 reactivation (PRIMA-1/APR-246, CP-31398, PEITC, ReACp53), and HDAC inhibitors to degrade mut-p53 (e.g., SAHA, CUDC-907); most have not been tested in GBM patients.
Methods
- Design: narrative review; no primary experimental data or systematic review methodology stated.
- Data/sample: synthesizes published literature and genomic datasets including TCGA/cBioPortal, GBM cell lines, patient-derived xenografts, mouse models, and clinical trials.
- Analysis: thematic synthesis of p53 pathway deregulation, GOF mut-p53 mechanisms, non-coding RNA regulation, and p53-targeted therapies.
Limitations
- Stated: GOF mut-p53 is understudied in GBM; most GBM p53 studies failed to distinguish TP53 deletion from GOF mutations; common mouse models rely on wt-p53 knockout rather than representative GOF knock-in models; exact timing of TP53 mutation in primary GBM is not discerned; p53 pathway therapeutic exploitation has not been very successful to date.
- Evident: as a narrative review, it does not report a systematic search strategy, inclusion criteria, or quantitative synthesis, and it draws on heterogeneous preclinical models and datasets.
- Evident: some cited findings are inconsistent (e.g., TP53 expression in recurrent tumors has inconsistent results; TP53 mutational status not correlated with GBM survival despite high mutation frequency), which limits firm conclusions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The p53 pathway is highly deregulated in GBM (adapted from cBioportal) [22,23]. The most common mutations of the p53 pathway are missense mutations in TP53, deletions of CDKN2A/ARF, and/or amplifications of MDM2 and MDM4. These mutations often lead to diminished tumor suppressor activity.](https://figures.cochat.ai/paper-figures/60f21ea91fb64b26b5e87bf2208c45eb/the-p53-pathway-in-glioblastoma-figure-1.jpg)
![Figure 2 The p53-ARF-MDM2/4 pathway (adapted from the p53 website) [24]. In response to hyperproliferative stress and/or DNA damage, pathway mediators, such as ARF, are activated. MDM2 and MDM4 mark p53 for degradation, and are subsequently degraded when upstream mediators are activated. This releases p53 from degradation, and leads to increased cell cycle arrest, apoptosis, DNA Repair, and cellular senescence.](https://figures.cochat.ai/paper-figures/770371f06cf34b1381e5d6e41fba4c45/the-p53-pathway-in-glioblastoma-figure-2.jpg)
![Figure 3 Most TP53 mutations are in the DNA binding domain. (A) The schematic view of the domains of p53 protein. The protein has 393 residues with numerous different domains including the N-terminus (red), proline rich domain (orange), DNA binding domain (purple), tetramerization domain (green) and negative regulatory domain/C-terminus (blue). The peaks represent the frequency of mutations in cancer with the DNA binding domain containing the six hot spot mutations. (B) Ribbon diagram of DNA-bound p53 (PBD ID 2AHI). The residues highlighted in yellow represent residues that are hot spot mutations as well as other residues of interest. Modified and reprinted with permission from Springer Nature: [Springer Nature] [Oncogene] [112].](https://figures.cochat.ai/paper-figures/ba1dfb65902e4ee98e4a54d1908a06d9/the-p53-pathway-in-glioblastoma-figure-3.jpg)

Verification
Claims the paper makes
44 Valid · 3 Not valid · 34 Not checked · 6 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“MDM2 targets p53 for degradation, acting as a negative regulator [27,41].”
§ The p53 Pathway in Glioblastoma > 2. P53 Role and Deregulation in GBM > 2.4. MDM2 and MDM4 Are Amplified in GBM and Negatively Regulate p53
What the sources say
- Not checked — no full text of the sourcecites [27] England, 2013, Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme, Tumour Biol. source
- Supportedcites [41] Crespo, 2015, Molecular and Genomic Alterations in Glioblastoma Multiforme, Am. J. Pathol. source
In the Growth Factor TKR Pathways section (page not provided), the paper calls MDM2 a negative regulator of TP53 and states that MDM2's nuclear entry leads to TP53 degradation. Together, these passages support the claim. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The analysis determined that GOF mut-p53 binds ETS2 for activation of chromatin remodeler genes such as MLL1, MLL2 (both H3K4 methyltransferases) and MOZ (an acetyltransferase).”
§ The p53 Pathway in Glioblastoma > 2. P53 Role and Deregulation in GBM > 2.6. Gain-of-Function Mut-p53 in Cancer and GBM
What the sources say
- Supportedcites [111] Zhu, 2015, Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth, Nature source
The Discussion states that GOF p53 binds directly to ETS2 and drives expression of chromatin-regulator genes, including MOZ. The “GOF p53 regulates MLL, MOZ, and histone PTMs” section reports that reducing ETS2 decreases expression of MLL1, MLL2 and MOZ; the paper also identifies MLL1 and MLL2 as H3K4 methyltransferases and MOZ as an acetyltransferase. Page numbers were not provided in our copy. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inhibition of mut-p53 with the small molecule PRIMA-1 exhibited greater antitumor effects in samples expressing PTEN, emphasizing their tumor promoting interaction [107].”
§ The p53 Pathway in Glioblastoma > 2. P53 Role and Deregulation in GBM > 2.6. Gain-of-Function Mut-p53 in Cancer and GBM
What the sources say
- Supportedcites [107] Huang, 2013, A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy, Neoplasia source
The Introduction explicitly states that PRIMA-1 had greater antitumor effects when PTEN was expressed in cancer cells. The PRIMA-1 results section reports that PTEN restoration enhanced its effects on growth and apoptosis in mutant-p53 U373 cells; the finding is therefore supported in that experimental setting. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Specifically, upregulation of CCL2 and TNFA resulted in elevated levels of microglia and monocyte-derived immune cell infiltration.”
§ The p53 Pathway in Glioblastoma > 2. P53 Role and Deregulation in GBM > 2.6. Gain-of-Function Mut-p53 in Cancer and GBM
What the sources say
- Partly supportedcites [105] Ham, S.W., Jeon, H.Y., Jin, X., Kim, E.J., Kim, J.K., Shin, Y.J., Lee, Y., Kim, S.H., Lee, S.Y., and Seo, S. (2018). TP53 gain-of-function mutation promotes inflammation in glioblastoma. Cell Death Differ. sourceExperimental — accuracy not yet measured
The “TP53 R248L promotes chemotaxis” section (page unavailable) reports increased microglial and HL60-derived immune-cell migration, as well as increased microglial and macrophage infiltration in some xenografts. The “TP53 R248L upregulates CCL2 and TNFA to promote chemotaxis” section (page unavailable) shows that both cytokines increased, but the infiltration experiment identifies CCL2—not TNFA—as the mediator; CD11b+ monocyte infiltration also did not increase significantly in one tumor model. The claim therefore overstates the evidence that upregulation of both cytokines caused the reported infiltration. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The prevalence of p53 mutations differs in the different GBM molecular subtypes (proneural, mesenchymal, neural and classical) (54%, 32%, 21% and 0%, respectively) [15].”
- Also stated in: § 2.6. Gain-of-Function Mut-p53 in Cancer and GBM · plain
“The prevalence of TP53 mutations also differs in the different GBM molecular subtypes (proneural, mesenchymal, neural and classical) (54, 32, 21 and 0%, respectively) [15].”
§ The p53 Pathway in Glioblastoma > 1. Introduction
What the sources say
- Partly supportedcites [15] Verhaak, 2010, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Cell sourceExperimental — accuracy not yet measured
The Results (Functional Annotation of Subtypes; page unavailable) report that TP53 mutations were frequent in Proneural samples and absent from the sequenced Classical samples, supporting a subtype difference. Our copy does not give the claimed mutation prevalences of 54%, 32%, 21%, and 0% across all four subtypes; its 54% figure refers instead to a chromosome 7/10 event in Proneural samples. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 2.6. Gain-of-Function Mut-p53 in Cancer and GBM · plain
44 more claims · 22 with their cited sources checked
Create a free account to see all 87 claims and to verify the 9 references still open.
- It may state two separate claims as one. 34
- Probably not a substantial claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These alterations include TP53 mutation (22%), amplification of MDM2 (10%) or MDM4 (9%), and/or CDKN2A/B homozygous deletion (60%).4,5”
From Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts (2026) · cites this paper as [4]
Experimental — accuracy not yet measured
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 2×
“However, mutations in all TP53 DBD codons have been reported in cancer [62].”
BackgroundThe p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Cited by
Sex differences in cancer mechanisms
Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00291-x · Cited by 366
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 287
“166 Targeting the p53/MDM2/p14ARF pathway represents a promising therapeutic avenue.”
Pouyan, A., Ghorbanlo, M., Eslami, M., Jahanshahi, M., Ziaei, E., Salami, A., Mokhtari, K., Shahpasand, K., Farahani, N., Meybodi, T. E., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02267-0 · Cited by 271
Mouse models of glioblastoma for the evaluation of novel therapeutic strategies
Haddad, A. F., Young, J. S., Amara, D., Berger, M. S., Raleigh, D. R., Aghi, M. K., & Butowski, N. A. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab100 · Cited by 203
TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα
Ji, J., Ding, K., Luo, T., Zhang, X., Chen, A., Zhang, D., Li, G., Thorsen, F., Huang, B., Li, X., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00606-w · Cited by 181
Metadata
- Authors
- Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., Grello, C., Oxford, M., Yuan, F., & Abounader, R.
- Affiliations
- University of Virginia (US)
- University of Virginia Cancer Center (US)
- Corresponding author
- Abounader, Roger
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2018-09-01
- Volume
- 10
- Issue
- 9
- Pages
- 297
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC6162501
- OpenAlex
- W2890896123
- Cited by
- 440
- References
- 158
- Citations by year
- 2026: 42 · 2025: 66 · 2024: 76 · 2023: 52 · 2022: 80 · 2021: 60 · 2020: 50 · 2019: 13
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (U01 CA220841, R01 NS045209)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- p53, glioblastoma, TP53 mutation, tumor suppressor, apoptosis evasion, genome stability, tumor microenvironment, cell migration and invasion, cancer stemness, microRNA, long non-coding RNA, prognosis, therapeutic target
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The p53 Pathway in Glioblastoma. https://app.cochat.ai/papers/10.3390/cancers10090297
- The paper
- Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., Grello, C., Oxford, M., Yuan, F., & Abounader, R. (2018). The p53 Pathway in Glioblastoma. Cancers. https://doi.org/10.3390/cancers10090297
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.